NCT03829891

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.

Detailed description

The investigators wonder in clinical hypoglycemic treatment for patients with hyperglycemia, whether to reduce fasting blood glucose or postprandial blood glucose first. In this study, subjects with type 2 diabetes mellitus in combination with oral medication will be treated with basic insulin to reduce fasting blood glucose, or with beinaglutide to reduce postprandial blood glucose, in order to find out which one of controling blood glucose can be more effective and observe the change of blood fluctuation.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Beinaglutide	1. Beinaglutide for 8 weeks, 2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )
DRUG	glargine	1. Glargine for 8 weeks, 2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )

Timeline

• Start date: 2018-08-07
• Primary completion: 2019-12-31
• Completion: 2020-12-04
• First posted: 2019-02-04
• Last updated: 2022-01-19

Locations

2 sites across 1 country: China